Identification of dipeptidyl peptidase-4 (DPP-4) inhibitors as potential antidiabetic agents using molecular docking study

Diabetes is a heterogeneous disease of carbohydrates metabolism that occurs owing to a deficiency of discharge of insulin or resistance to it. Type 2 Diabetes Mellitus is very common and is a major concern. A patient over the age of 40 years mainly suffers from this and it is also increased with the increase in age and increase in obesity. Targeting to the disease progressing enzyme or protein is a valuable tool to alleviate the disease. Among several targets for diabetes, DPP-4 is recognized to control glucose metabolism. It degrades the GLP-1 or incretin which is supposed to be involved in glucagon release inhibition as well as augmented insulin secretion. Thus DPP-4 inhibitors like saxagliptin and sitagliptin are inhibiting DDP-4 leads to improve glycemic control. Therefore we have designed different novel DPP-4 inhibitors based on alogliptin which act as an antidiabetic agent with the help of Autodock vina molecular docking software. Among studies designed molecules, ANK4 showed good binding affinity (-10.7 kcal\mol) which is better than alogliptin (-9.6 kcal/mol).